A detailed history of Wolff Wiese Magana LLC transactions in Biogen Inc. stock. As of the latest transaction made, Wolff Wiese Magana LLC holds 2 shares of BIIB stock, worth $457. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2
Previous 2 -0.0%
Holding current value
$457
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 08, 2023

SELL
$252.44 - $306.72 $88,101 - $107,045
-349 Reduced 99.43%
2 $0
Q3 2022

Oct 26, 2022

SELL
$194.69 - $268.46 $6,814 - $9,396
-35 Reduced 9.07%
351 $94,000
Q2 2022

Jul 15, 2022

SELL
$187.54 - $223.02 $14,628 - $17,395
-78 Reduced 16.81%
386 $79,000
Q4 2021

Jan 18, 2022

SELL
$223.92 - $287.77 $1,119 - $1,438
-5 Reduced 1.07%
464 $111,000
Q2 2021

Jul 15, 2021

SELL
$259.0 - $414.71 $4,403 - $7,050
-17 Reduced 3.5%
469 $163,000
Q4 2020

Jan 27, 2021

BUY
$236.26 - $355.63 $114,822 - $172,836
486 New
486 $119,000

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $33B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Wolff Wiese Magana LLC Portfolio

Follow Wolff Wiese Magana LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wolff Wiese Magana LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wolff Wiese Magana LLC with notifications on news.